SOURCE: Lombard Medical Technologies PLC

November 18, 2013 02:06 ET

Lombard Medical: Formal US Launch of Aorfix at VEITH Symposium

LONDON, UNITED KINGDOM--(Marketwired - Nov 18, 2013) -

                  Lombard Medical Technologies PLC
                  ("Lombard Medical" or "Company")

Lombard Medical Announces Formal US Launch of AorfixTM at VEITH

The Only FDA Approved Endovascular Stent Graft for Use in Challenging
Abdominal Aortic Aneurysm Cases

London, UK and Irvine, CA, November 18, 2013 - Lombard Medical
Technologies PLC (AIM: LMT), the specialist medical device company
focused on the treatment of abdominal aortic aneurysms (AAAs), today
announces a stand-alone symposium and program of presentations to mark
the formal US launch of AorfixTM, the Company's flexible stent graft, at
the 40th Annual VEITH Symposium, November 19-23, New York Hilton
Midtown Hotel, Manhattan, New York City.

CEO of Lombard Medical Technologies, Simon Hubbert, commented:"Published
clinical data suggest that up to 30% of patients present
with tortuous AAA anatomy. US physicians now have access to Aorfix, a
highly effective, FDA approved treatment option for such cases. VEITH
Symposium is one of the most important annual gatherings of vascular
surgeons from around the world and the ideal venue to formally launch
Aorfix in the US."

Aorfix was approved by the US FDA in February this year and includes a
unique label indication for the treatment of patients with neck
angulations up to and including 90 degrees. Lombard Medical will be
hosting a launch stand-alone symposium, where leading physicians will
present clinical data and provide their first-hand experience of
Aorfix, on Thursday November 21, 12:00 noon to 1:00 PM.

Clinical discussions at the launch stand-alone symposium will be led by
key investigators from the Pythagoras US clinical trial of Aorfix,

   * Overall 1-year results of the Aorfix Pythagoras PMA Study - Mark
     F. Fillinger, M.D. Director, Vascular Surgery Training Programs,
     Professor of Surgery, Geisel School of Medicine, Dartmouth and
     Principal Investigator for Lombard's PMA Trial

   * Anatomical angles and effect on Aorfix PMA Study results -
     Mahmoud B. Malas, M.D. Chief of Endovascular Surgery and Director
     of Vascular and Endovascular Clinical Research, Johns Hopkins
     Bayview Medical Center

   * Gender and its impact on Aorfix PMA Study outcomes - William D.
     Jordan Jr., M.D. Professor of Vascular Surgery, University of
     Alabama School of Medicine

   * Access techniques for tortuous anatomy - Jeffrey P. Carpenter,
     M.D. Chairman and Chief, Department of Surgery, Cooper University
     Health Care

   * Clinical insights from the Aorfix PMA Study - Kim J. Hodgson,
     M.D. Professor and Chair, Division of Vascular Surgery, SIU School
     of Medicine

In addition, Lombard Medical will host a meeting and product
demonstration for investors and analysts on November 20, 2:30 PM to
4:30 PM at the Hilton hotel, no new material financial or other
information will be disclosed.

The following presentations highlighting Aorfix will also take place at
this year's VEITH Symposium on Friday November 22:

   * Advantages and Limitations of the Lombard Aorfix Endograft. Now
     FDA Approved in the US - Mark F. Fillinger, M.D. Director, Vascular
     Surgery Training Programs, Professor of Surgery, Geisel School of
     Medicine, Dartmouth and Principal Investigator for Lombard's PMA

   * Challenging Anatomy: Can Freedom from Adjunctive Fixation mean
     Freedom from Migration and Endoleak? - Prof. Brian R. Hopkinson,
     M.D., Emeritus Professor of Vascular Surgery, University of
     Nottingham; Consultant Vascular Surgeon, Queen's Medical Centre,
     Nottingham, United Kingdom


For further information:

Lombard Medical Technologies PLC                 Tel: +44(0)1235 750 800
Simon Hubbert, Chief Executive Officer
Ian Ardill, Chief Financial Officer

Canaccord Genuity Limited                        Tel: +44(0)20 7523 8000
Lucy Tilley / Tim Redfern / Henry Fitzgerald O'Connor
/ Dr Julian Feneley

FTI Consulting                                   Tel: +44(0)20 7831 3113
Simon Conway / Stephanie Cuthbert / Victoria Foster

Allen & Caron                                     Tel: +1 (949) 474 4300
Matt Clawson

About VEITH Symposium

Now in its fourth decade, VEITH Symposium provides vascular surgeons,
interventional radiologists, interventional cardiologists and other
vascular specialists with a unique and exciting format to learn the
most current information about what is new and important in the
treatment of vascular disease. The 5-day event features 430 rapid-fire
presentations from world-renowned vascular specialists with emphasis on
the latest advances, changing concepts in diagnosis and management,
pressing controversies and new techniques. To register to attend VEITH
Symposium, please visit .

About Abdominal Aortic Aneurysms

AAAs are a balloon-like enlargement of the aorta which, if left
untreated, may rupture and cause death. Approximately 4.5 million
people are living with AAAs in the developed world and each year
600,000 new cases are diagnosed.

In the U.S. aortic aneurysm disease is among the leading cause of death
and it is estimated that 1.7 million people over the age of 55 have
abdominal aortic aneurysms. According to independent market research,
the U.S. AAA market is estimated at more than $600 million annually and
is forecast to grow to $1.6 billion worldwide by 2015.

About Lombard Medical

Lombard Medical Technologies PLC (AIM: LMT) is a medical device company
focused on device solutions for the $1.3 billion per annum abdominal
aortic aneurysm (AAA) repair market. The Company's lead product,
Aorfix, is an endovascular stent graft which has been specifically
designed to solve the problems that exist in treating complex tortuous
anatomy, which is often present in advanced AAA disease. Aorfix is the
only stent graft approved for AAA neck angulations of up to 90 degrees
and is currently being commercialized worldwide. Aorfix is the first
AAA stent graft not of U.S. origin to gain FDA approval. The Company is
headquartered in Oxfordshire, England with U.S. operations in Irvine,

Further background on the Company can be found at .

                    This information is provided by RNS
          The company news service from the London Stock Exchange


Contact Information